Verrica Pharmaceuticals Inc. Common Stock earnings per share and revenue
On Nov 14, 2025, VRCA reported earnings of -0.03 USD per share (EPS) for Q3 25, beating the estimate of -0.68 USD, resulting in a 95.64% surprise. Revenue reached 14.34 million, compared to an expected 5.96 million, with a 140.70% difference. The market reacted with a -5.09% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -0.81 USD, with revenue projected to reach 4.62 million USD, implying an increase of 2600.00% EPS, and decrease of -67.82% in Revenue from the last quarter.
FAQ
What were Verrica Pharmaceuticals Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Verrica Pharmaceuticals Inc. Common Stock reported EPS of -$0.03, beating estimates by 95.64%, and revenue of $14.34M, 140.7% above expectations.
How did the market react to Verrica Pharmaceuticals Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -5.09%, changed from $3.93 before the earnings release to $3.73 the day after.
When is Verrica Pharmaceuticals Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 26, 2026.
What are the forecasts for Verrica Pharmaceuticals Inc. Common Stock's next earnings report?
Based on 7
analysts, Verrica Pharmaceuticals Inc. Common Stock is expected to report EPS of -$0.81 and revenue of $4.62M for Q4 2025.